Aratana Therapeutics (PETX) Tops Q3 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q3 EPS of ($0.38), $0.10 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c